ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年07月27日 12時00分
Source:
Eisai
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に19年連続で選定
東京, 2020年07月27日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来19年連続で選定されましたのでお知らせします。
「FTSE4Good Index Series」は、環境・社会・ガバナンス(ESG)のグローバル・スタンダードを満たす企業への投資を促進するようデザインされた株式指数シリーズです。当社は評価項目のうち、「人権と地域社会」、「労働基準」、「コーポレートガバナンス」、「腐敗防止」および「気候変動対策」などの項目において特に高い評価を受けました。2020年7月現在、世界で1,075社、日本企業ではそのうち192社が「FTSE4Good Developed Index」に選定されています。
当社は、「FTSE4Good Index Series」以外にも年金積立金管理運用独立行政法人(GPIF)によって採用されている日本株の4つのESG投資指数である「MSCI 日本株女性活躍指数(WIN)」、「FTSE Blossom Japan Index」、「MSCIジャパンESGセレクト・リーダーズ指数」および「S&P/JPXカーボンエフィシエント指数」にも選定されています。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。当社は、この理念の実現のために、ESGへの取り組みを強化し、非財務価値を高めることにより、持続的企業価値向上に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202046.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
Fujitsu collaborates with global suppliers in decarbonization initiative to exchange product-level primary data on CO2 emissions
Nov 15, 2024 10:13 JST
TANAKA Successfully Develops the World's First[1] Manufacturing Technology for Platinum Materials with Nano-Sized Crystal Grains
Nov 15, 2024 04:00 JST
myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth
Nov 14, 2024 20:00 JST
ULVAC Launches Oil Rotary Vacuum Pump Gv135
Nov 14, 2024 10:00 JST
MHI Publishes MHI REPORT 2024
Nov 13, 2024 16:52 JST
SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization
Nov 13, 2024 12:38 JST
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 12:05 JST
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 13, 2024 11:16 JST
All-New Triton Wins Special Award at the RJC Car of the Year for 2025
Nov 12, 2024 22:09 JST
Toyota: HySE to participate in the Dakar 2025 "Mission 1000 ACT2" with the HySE-X2, to tackle further technical challenges
Nov 12, 2024 20:04 JST
NEC participates in COP29 climate change conference
Nov 12, 2024 19:25 JST
JA Mitsui Leasing and Fujitsu collaborate on simulation-driven field trials to optimize commercial EV adoption and drive decarbonization
Nov 12, 2024 13:57 JST
More Latest Release >>
Related Release
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
10/31/2024 1:56:00 PM JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/31/2024 11:33:00 AM JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
10/17/2024 8:01:00 PM JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
10/17/2024 3:59:00 PM JST
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
10/16/2024 7:14:00 PM JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
10/8/2024 2:00:00 PM JST
More Press release >>